compani profil focu
sentiment remain quit neg biopharma follow tough nbi
drg look expect modest
fundament backdrop solid set group well report provid
one-pag profil compani coverag barclay global
univers includ us biopharma us smid cap eu pharma highlight
key event potenti valu drivers/catalyst differ consensu
thought broader industry-specif trend year found
see multipl upsid potenti includ higher royalti novarti avxs-
sma higher price robust launch success ip extens posit
cohort wetamd data progress partner program sarepta
cautiou dmd gene therapi program believ sarepta set high bar
like meaning first market advantag addit upsid potenti multipl
catalyst includ ppmo lgmd golodirsen approv bluebird despit
increas competit bcma-target therapi mm continu view
best like first market strong partner see
signific upsid celgen remain commit move earlier line mm
addit upsid higher price lentiglobin bt/scd
alexion launch ultomiri pnh approv dec allay ip competit
overhang soliri growth gmg nmo adopt drive upsid
celgen expand indic revlimid pomalyst otezla help beat
expect launch prepar luspatercept ozanimod fedratinib could
restor confid eas long-term revlimid revenu concentr worri lilli
continu differenti growth profil biopharma driven new
product cycl set good upsid potenti seattl re-focus
commerci effort adcetri hodgkin new launch
set stage adcetri upsid data file ev urotheli cancer
provid next wave portfolio expans
eu pharma papadakis/field favorit name azn despit failur
mystic astra product stori remain key key commerci asset
perform well help trajectori within oncolog offer good risk-
reward profil ahead addit upcom data-point includ io doublet
kestrel lynparza polo pancreat volatil genmab
failur darzalex solid tumor remain overhang sentiment remain
posit molecul underli growth stori given posit recept
maia present suspect could see inflect script
follow addit data label file expect
barclay capit inc and/or one affili seek busi
compani cover research report result investor awar
firm may conflict interest could affect object report investor
consid report singl factor make invest decis
research report prepar whole part equiti research analyst
base outsid us registered/qualifi research analyst finra
expect
ip protect humira
light ip headwind continu face humira think fare well
emerg sever challeng rel unscath inde continu
addit settlement biosimilar
manufactur us like push competit launch
us overhang rel remov near-term focu begun shift
back pipelin biosimilar launch eu remain top mind investor
remain biggest valuat driver near term recogn abbvi
potenti near-term win horizon could improv sentiment orilissa
launch mavyret trajectori risankizumab/upadacitinib launch think share
perform larg tie humira franchis given perceiv
pipelin unlik suffici off-set futur eros view share fairli valu
current level maintain equal weight rate move
respect pipelin beyond point recent failur
rova-t program sclc significantli impact share given
street peak revenu opportun altern recent progress immunolog
upadacitinib risankizumab launch anticip could help off-set lost ou
humira revenu orilissa repres addit revenu opportun approv
think could begin multi-billion dollar franchis women
health initi demand slower anticip thu far
view loom uncertainti humira eu biosimilar eros curv remain
import risk near term point recent provid
visibl ou humira expect manag earn call
novemb helpfulwith estim declin vs prior
dramat eros expect vs previous ultim
remain wari humira outlook think share could see pressur
come month biosimilar launch continu progress price discount reset
across europ given recent experi eu biosimilar adopt wouldnt
surpris see ou humira take anoth leg forecast q/q
y/i discount major unprotect market potenti reach high
view
term market reach sever settlement key biosimilar
competitor compani regard ligat global ip humira cours
ultim delay entranc biosimilar humira earli
first begin januari rest stagger throughout view
settlement larg repres remov key overhang
clariti compani expect biosimilar competit
market think increasingli unlik see biosimilar product
success come market
valuat thought
go view share fairli valu line ew
thesi look forecast revenu vs consensu
non-gaap ep vs consensu
expect
acceleron outperform nbi index vs year compani
report impress pivot data luspatercept myelodysplast syndrom md
medalist beta-thalassemia believ latest review see thought
luspatercept confer call among key takeaway md
patient beta-th patient achiev transfus independ
kol expect follow channel check set could robust
launch total sale vs consensu vs consensu
view could boost share head next year given
guidanc us/eu file drive conserv launch time expect
earlier stage pipelin potenti move forward
think xlrn share price like reflect valu luspatercept program
modest expect potenti label expans earlier md patient md
medalist non-transfus depend beta-th beyond said readout
earlier stage program could start build excit pipelin beyond
luspaterceptfurth drive share upsid phase data expect
facioscapulohumer muscular dystrophi fshd charcot-marie-tooth cmt
could help de-risk muscl program sotatercept phase data
pulmonari arteri hypertens pah wont come make unlik
major upsid driver although enrol increas allow potenti
file base phase dataunlik view see thought acceleron
pah day timelin potenti read-out make unlik
contributor share perform
valuat thought
price target base npv analysi forecast risk-
adjust sale luspatercept md beta-th begin assum us
eu regulatori submiss fda approv also forecast risk-
adjust sale sotatercept ckd pah assum potenti launch
forecast sale conserv assum termin valu also forecast
probabl adjust sale fshd potenti launch use
discount rate reflect risk program given assumpt
deriv valuat luspatercept sotatercept
net cash npv
support price target
expect
neg ye sentiment set stage pivot
challeng achillion share end decemb trade yearli
low vs nbi index level less cash valu compani
recent quarter much neg sentiment view driven
compani announcementdur strateg updat mid-decemberthat
evid clinic benefit later-stag asset insuffici
support develop monotherapi pnh see achn progress posit
data limit factor program
view achillion factor inhibitor program one intrigu approach
moder complement pathwaywith signific upsid potenti given unmet
need soliris/ ultomiri refractory/ resist pnh patient recent review see alexion
pharmaceut defin pnh landscap howev given
clinic develop challeng space along sever histor failur
includ alnylam cover us smid cap analyst gena wang expect
investor skeptic persist achillion absent signific de-risk portfolio
develop continu see along advanc
next-gen portfolio regulatori clinic updat could go long way toward
reassur investor valu achillion platform
reveal potenti pnh combin question
market potenti unlik address
phase combin soliri continu week data
anticip expect although admittedli market outlook unclear given
alexion ultomiri approv pnh channel check suggest rapid
uptak switch soliri see thought ultomiri approv
proof-of-concept studi glomerulopathi enrol
manag target end-of-phas meet fda look
potenti boost stock clinic data clearli posit rapid uptak
ultomirismay limit stock upsid pnh combin data highli favor
preliminari data next gener program may also provid upsid
beyond compani bullish next-gener inhibitor achn-
higher potenc support bid qd dose vs tid phase mad
track start ind anticip submit
manag plan move patient pnh monotherapi trial elect
remain treatment via lte earli compani set begin ind-
enabl work goal start phase mad
valuat thought
price target achn base sum-of-th part npv analysi deriv
valu base compani cash posit also deriv valu
compani pipelin primarili consist factor complement
inhibitor phase pnh next- gener
result pt
beyond manag anticip suffici cash support develop
plan like ye reserv project burn
leav meaning potenti upsid clinic regulatori event come
year prove posit
expect
despit execut well multipl front good cadenc upsid quarterli
perform posit phase pnh data ultomiri earli approv
ultomiri acquisit wilson therapeut syntimmun expand
pipelinealexion share still lost year vs nbi index
primarili worri competit landscap complement ip concern
soliri decis come eu look anticip robust
patient switch soliri ultomiri drive franchis forward provid
higher barrier entri competit threat continu see near-term competit
threat minim anticip entrant market sever year away
overal see alexion orphan drug busi one highest qualiti growth
franchis biotech good upsid potenti consensu revenu growth
non-gaap ep base soliri growth primarili gmg lesser
extent nmo consensu ultomiri adopt expect
new product cycl expand pipelin multipl
estim view share attract support ow rate pt
success switch patient soliri ultomiri allevi concern
understand concentr risk soliri franchis revenu
provid overhang stock due competit threat expect sentiment
chang approv ultomiri extend life-cycle franchis
entrench alexion leader complement space order facilit
transit acceler switch soliri alexion price ultomiri discount
soliri discount combin favor dose schedul everi week
compar everi week soliri provid addit barrier competitor
like requir demonstr non-inferior even superior gain
signific traction dont think current expect ultomiri sale
look aggress whatsoev
pipelin expans diversifi compani reduc concentr risk
addit switch patient soliri ultomiri alexion de-risk
competit overhang continu build asset indic soliri alexion
expect regulatori file nmosd earli suspect approv timelin
could fast given unmet medic need ultomiri phase top line result ahu
expect well trial initi ultomiri myasthenia gravi earli
furthermor asset syntimmun acquisit set initi two pivot
trial
valuat thought
valu share base sum-of-th part npv analysi forecast sale
soliri strensiq kanuma includ termin valu
use discount rate forecast period think appropri reflect
risk portfolio termin valu assum less growth rate
discount rate deriv valu soliri
strensiq kanuma combin net cash
result total npv share
expect
one top perform large-cap biotech outperform nbi
index vs despit modest top-lin revenu growth last year amgen
appear set grow non-gaap ep driven combin lower tax
declin tax expens share buyback although number clear
success regard pipelineinclud approv aimovig migrain
advanc number oncolog asset includ car-t bispecif antibodi oral
small molecul bispecif t-cell engag bite rel earli
stage asset news flow unlik drive share upsid justifi
equal weight rate
view stock perform like reflect progress new
growth product extent declin legaci busi forecast
signific sale declin legaci product enbrel vs con
neulasta vs con epogen vs con aranesp vs con
vs con offer addit overhang two
neulasta biosimilar approv fulphila coheru
udenyca contribut neulasta sale compound-annual-growth-rate
in-lin consensu despit launch aimovig sale
vs con sale growth repatha vs con
project total sale declin wors consensu given pressur
legaci franchis
although new productsnot proliamay off-set declin anticip
headwind new launch notic repatha discount unlik
drive concomit increas volum near term see thought repatha
price cut similar competit pressur discount sampl anti-
cgrp antibodi migrain like limit aimovig sale near-term see
capit alloc like remain key focu
continu amass cash upward balanc sheet even execut
tender offer repurchas outstand share march
reason capit alloc like major driver share perform larg
transact near-term revenu accret asset would boost share perform
doubt trade revenu growth signific dilut contrast gilead
also larg cash stockpil need top-lin growth drive number
recent partnership acquisit notabl kite conserv
balanc sheet manag broadli discuss deal also note
high valuat target space desir overpay point
return cash form dividend recent increas shown
prefer share repurchas view larger disrupt deal may need
chang convers investor shift focu back growth
valuat thought
price target base price-to-earnings multipl analysi support sum-
of-the-part npv analysi view signific upsid forward multipl unlik
given lack compel growth price competit expect near term
kyproli repatha biosimilar risk establish franchis price target assum
trade approxim ep
expect
encourag bausch strong commerci perform recent quarter larg
ahead street expect build strong commerci
year expect
manag aggress cash flow plan debt repay strategi view
favor investor bring current total debt level expect
compani continu approach toward debt repay forese futur
wed character manag overal tone recent convers quit favor
given new product launch see strong product uptak believ
off-set expect pressur overal view continu
commerci perform anoth posit step right direct bausch
remain encourag compani overal growth profil posit head
maintain overweight rate pt
highlight sever pipelin updat new products/rec launch view
character potenti valu driver overal busi includ recent launch
lucemyra august aqualox sihi daili septemb japan plenvu
septemb doptelet octob altreno octob expect
launch bryhali anticip novemb duobrii pdufa februari
valuat thought
maintain ow rate bausch share given increas posit outlook
follow strong commerci perform throughout year current price target
base ebitda forecast adjust ep
total revenu
expect
share margin outperform nbi index vs given stabil
core ms franchis good growth spinraza pipelin surpris look
consensu expect ms arent aggress growth even
given strong adopt roch ocrevu ww spinraza growth expect also
look reason ou us growth outer year forecast less certain given
sma competit landscap beyond franchis excel expand
pipelin past month adding/advanc clinic stage asset stroke
epilepsi al psp parkinson neuropath pain among other product
neurosci focu differenti among biopharma peer view said
program collect less impact investor compar alzheim
portfolio name aducanumab outsiz impact sentiment cours
npv result upsid quarterli perform diroximel fumar ms
approv mid de-risk data al psp less like
multipl expand share view inde think multipl
estim peer look reason revenue/non-gaap ep
growth profil support ew rate
alzheim option time everyth
remain non-committ regard interim analysi engag emerg
two phase program aducanumab alzheim diseas formal comment
final data could avail month use earn call oct
refer point view given upsiz trial spring
dose interv cours long histori phase failur alzheim wed look
late earli realist time-frame final matur interim top-lin
data still would put po base phase prime data recent
updat ctad meet see thought aducanumab prime ctad
updat show good durat effect dont give much valu
phase need elenbecestat less optim bace inhibitor
hard ignor option aducanumab look view
note modest part npv analysi consensu forecast assum
sale sale vari level probabl adjust
recent file approv could help add durat
ms franchis unlik add much upsid forecast mid
approv dont view celgen ozanimod ad much uncertainti ms market
late tau program hot target alzheim includ
unlik much poc data except
could proof concept data psp beyond current pipelin
note sever occas ampl capac deal look
next five year capac invest intern extern
highlight thu far extern bd smaller scale wed view deal
grow commerci stage product favor given need add
meaning asset growth revenu base off-set clinic risk alzheim
valuat thought
valu forward pe basi assum share trade modest discount
turn rel averag forward large-cap biopharma group price-to-earnings multipl
support pt
expect
set stage potenti rimegep commerci
strong year biohaven vs nbi index look
momentum continu past year compani report posit phase
data rimegep small molecul cgrp receptor antagonist see thought
biohaven follow phase rimegep data also report posit phase
data oral dissolv tablet formul confirm initi good
phase efficaci safeti profil see thought rimegep data
similar long-term safeti result posit address concern
possibl liver toxicitiesperceiv issu classwith result also
suggest potenti role migrain prevent see thought rimegep
given appar advantag standard care option name triptan
rimegep appear well posit address acut migrain treatment market
us patient potenti upsid prevent market
look start provid insight competit regulatori dynam
compani plan submit nda oral formul like end
potenti launch potenti acut market like nearli
fulli assum bhvn share price phase rimegep migrain prevent
start potenti read-out capabl drive upsid stock
especi given kol suggest oral would like signific cost
administr advantag antibodi prevent market see amgn/lli
takeaway migrain physician lunch
troriluzol updat like begin clarifi upsid asset
beyond rimegep expect number updat rest pipelin last
novemb fda accept nda submiss nurtec/
sublingu form riluzol al pave way potenti approv asset
previous grant orphan design migrain phase nasal formul
next gener anti-cgrp asset set start
increment updat also expect compani glutam portfolio phase
nmda receptor antagonist variou indic like complet
updat plan earli phase troriluzole/ ocd
continu enrol similar studi spinocerebellar ataxia set start enrol
januari anoth phase gener anxieti disord expect initi
on-going alzheim phase futil analysi anticip
readout given initi neg data ataxia consid troriluzol
program higher risk updat unlik complet de-risk
program year provid greater insight potenti asset see
 thought biohaven day
valuat thought
price target base npv analysi forecast risk adjust sale
rimegep treatment episod migrain begin end
also assign broader platform includ potenti indic trigriluzol
al use discount rate line biotech peer
size develop stage given assumpt deriv valuat
rimegep broader platform net cash
result npv support price target
expect
bioxcel set well head key asset set enter clinic
first year trade share end year march ipo vs
nbi index time frame view under-perform less
bioxcel reflect neg sentiment low risk appetit smid cap
biotech combin lack liquid overal continu posit
bioxcel follow initi compani make solid progress two
lead program neurolog asset immuno-oncolog see bioxcel
therapeut inc initi overweight program track
think compani set well continu make progress pipelin
continu evolut toward matur commerci stage biotech
iv data healthi volunt schizophren see thought
phase data support sublingu ind look bridg
bioequival data follow subsequ registr studi support
last week decemb compani report fda
award track design upsid like recogn
follow like nda submiss continu flow posit news
continu bolster support compani underli ai platform identifi
potenti clinic candid partial de-risk preliminari
efficacy/safeti data although admittedli lower risk rel clinic
valid technolog provid investor boost
proof-of-concept data tnepc could drive upsid
progress also decidedli posit among key event fda
accept ind novemb pave way clinic studi next year
offer signific de-risk data proof concept phase data
combin keytruda treatment-emerg neuroendocrin prostat cancer
tnepc avail potenti greater stock upsid
valuat thought
price target base npv analysi forecast risk-
adjust sale agit begin assum pivot data earli
fda approv year exclus also forecast risk-
adjust sale prostat neuroendocrin pancreat cancer assum
potenti launch forecast sale conserv assum termin
valu use discount rate given earli stage program given
assumpt deriv valuat net
cash npv support price target
expect
share seem resili middl despit underwhelm nsclc
data stock difficult base string neg news
pertain lead asset opdivo admittedli current commerci outlook
earli seem rel posit evidenc guidanc rais resili
opdivo sale anticip share perform increasingli tie
grow uncertainti broader posit i/o beyond nsclc rcc
market view increas skeptic opdivo trajectori beyond
remain signific overhang share wouldnt surpris see share trade
in-rang recogn stock may seem attract current level would
caution investor given perceiv unfavor risk/reward profil ahead
multipl high-impact readout potenti year particular emphasi nsclc
part rcc late though
still signific revenu opportun i/o long term data trial
may fall short efficaci threshold would need impact domin share
merck keytruda limit event horizon think could contribut re-
rate share maintain equal weight outlook
opdivo uncertainti beyond like weigh share
opdivo potenti revenu opportun lung well key indic like rcc
remain top mind investor especi look opdivo commerci outlook
beyond think investor apprehens loom quit time
sever high-impact question suffici address name much share
lung market bristol get peak think magnitud
eros lung market like pretti signific keytruda share
ramp opdivo yervoy share rcc remain strong given recent data
detail result expect soon provid clariti potenti market dynam
tmb success implement widely-us biomark light
minim differ os hazard ratio tmb high low patient
pipelin beyond i/o unlik move dial
dont anticip mani signific oper shift virolog sale
continu declin given hcv market dynam on-going loe pressur noac
dynam could potenti alter given move jnj xarelto novel popul
continu expect eliqui post solid growth consensu orencia
larg fallen radar think posit given intensifi anti-tnf
biosimilar competit nevertheless consensu forecast impli growth
valuat thought
valu share use blend averag price/growth basi base averag
larg cap global therapeut group view appropri given
primari focu specialti drug/biotechnology-ori compani discount
cash flow analysi appli averag price/growth multipl peer group suggest
valu per share dcf analysi suggest intrins valu per share
assign equal weight two methodolog deriv price target
expect
celg share dramat under-perform vs nbi index mostli
given concern revlimid ip durat risk also pipelin execut rtf
ozanimod multipl sclerosi ms delay bla file liso-cel dlbcl
clearli pressur multipl peer despit celgen differenti
growth profil revenu compound-annual-growth-rate peer look think
revlimid settlement dr reddi could remov shorter-term overhang
fundament launch prepar new product includ luspatercept b-thal
md ozanimod ms fedratinib mf could go long way help restor investor
confid addit upsid also seem like driven recent phase
success revlimid pomalyst otezla look reason expect
revenu non-gaap ep overal believ progress toward
greater revlimid diversif biggest impact multipl expans
accept file luspatercept ozanimod fedratinib regulatori review
phase success myeloma major valu driver year
commerci execut help stabil multipl
lower long-term guidanc fall big blow sentiment
cours thought commerci execut solid expect
continu highlight sever new driver includ abraxan greater io
combo use possibl phase success adjuv pancreat otezla scalp psoriasi
behcet diseas adopt revlimid non-myeloma indic fl new
launch like bias near-term expect low luspatercept
ozanimod fedratinib
think look beatabl
pipelin need continu progress
bcma race myeloma quit evid meet decemb
notabl celgen remain clearli lead karmma phase
studi underway could initi launch progress
critic part celgen stori provid rapid
diversif revlimid later stage pipelin wed point zero expect cc-
abraxan adjuv pancreat could read time
minim expect liso-cel celmod platform clearli celgen could expand
pipelin bd deal product acquisit especi given
view investor would prefer see execut deal alreadi
complet failur nogra pharma deal highly-
competit process rtf phase delay ozanimod recepto made
investor cynic celgen extern strategi
valuat thought
price target base price-to-earnings multipl support sum-of-th
part npv analysi use wacc termin valu
expect
perform like hing viaskin peanut bla outlook
dbv end difficult spot although compani receiv posit regulatori
feedback regard viaskin peanut clinic data enabl octob bla submiss
compani voluntari withdrew applic decemb see dbvt fda show
dbvt littl love voluntari decisionwhich follow verbal written
feedback agenc addit data regard manufactur procedur
qualiti control would requiredneg impact share end year far
nbi index vs nbi index see dbv technolog bla
withdrawn move ew
thu set-up pivot year dbv attempt get clinic program
back track follow-up discuss manag offer littl way timelin
ad still review fda comment would muster addit
resourc resubmit applic quickli possibl therefor look
updat near futur plan next step along specif time-lin despit
impact uncertainti dbvt share announc substanti delay
could neg impact stock especi given compani limit current
cash posit eur end septemb rais potenti need
capit rais futur convers outlook short-turn around like offer
consider support stock especi given report fda indic
clinic data would necessari
overal continu posit viaskin platform market opportun
across portfolio beyond viaskin peanut compani plan engag regul
next step viaskin milk start clinic develop viaskin egg
posit feedback would certainli help bolster stock given regulatori
uncertainti look share continu trade rang clariti provid
valuat thought
target price base sum-of-th part npv analysi valu dbvt
viaskin peanut us program viaskin milk combin
project net cash posit support pt
expect
even given strong perform think lilli remain one
compel straightforward invest case space driven underli
volume-bas growth new product cycl new product expect drive roughli
growth minim expect beyond
reflect one slower year long-term guidanc period revenu compound-annual-growth-rate
vs forecast see meaning room out-performance
cours yearand diabet competition/pr pressur remain key risk
multi-product cycl invest thesi new product launch across immunolog
oncolog neurolog underpin assumpt revenu acceler
continu like lilli posit head given differenti revenue/ep
growth profil multipl near-term upsid driver carri posit sentiment
view expect margin improv guidanc
elanco spin prove anoth posit catalyst earli part
year given expect acceler revenu growth/margin upsid new product
launch tanezumab tirzepatid earn upsid potenti continu
make compel invest case near long term support
guidanc alreadi issu wed character outlook strong
especi increas dividend help keep investor sentiment quit
posit despit recent market volatil view midpoint
billion revenu rang growth y/i midpoint beatabl rel known
headwind includ competit novo nordisk cover eu pharma
analyst emmanuel papadaki ozemp sever loeswith potenti tailwind pois
outweigh risk expect headwind
new product cycl among best biopharma
beyond label expans notabl new asset taltz forecast
verzenio point continu domin trulic
post-rewind potenti upsid migraine/pain franchis given minim
expect key driver growth view lasmiditan well-posit
benefit like emgal expans episod cluster headach potenti offer
differenti migrain portfolio profil capabl captur meaning share
tanezumab outlook con remain conserv ahead greater clariti
potenti label think clear efficaci reason safeti profil could support
anti-ngf market potenti upsid addit think mirikizumab
pegilodecakin remain investor radar despit recent data support il-
class tremfya potenti first-in-class posit class
valuat thought
maintain price target lilli reflect blend averag
price-to-earnings multipl dcf-base methodolog assum current year price-to-earnings
multipl sustain forward year earn suggest valu similar
intrins valu base dcf
lilli alreadi provid explicit margin op ex guidanc dont
anticip meaning shift guidanc revis like put hold
see visibl potenti improv even recent
provid guidanc meaning street expect think lilli room
beat current rang top-lin bottom
expect
gilead share gener track nbi
index margin rel
under-perform vs nbi index hep franchis final stabil
pipelin matur chang hep dynam import view given multi-
year obsess demand trend competit new start access etc wasnt
surpris given hep revenu trajectori peak
eros view stabil hep franchis lower
base highlight gilead robust hiv franchis barclay
clear path yescarta pipelin posit impact growth
look number posit develop gilead could
multipl expand includ new chairman ceo daniel oday roch
start march return growth barclay revenu non-
ep hasnt seen y/i basi sinc multipl high-impact
phase readout includ filgotinib ra selonsertib nash descovi
hiv prep henc look past futur gilead think
could break-out year fundament sentiment perspect
expect biktarvi success continu given rapid ascent prescrib
regimen naiv switch us broader eu roll-out follow june
approv consensu expect call growth ww sale
ou adopt like upsid potenti consensu view
dont view recent coverag plan unit see thought
unitedhealthcar hiv program hiv risk factor look forecast
hiv guidelin patient experi favor taf-contain regimen
vs tdf-base regimen inde feedback hiv specialist biktarvi
univers good see gilead scienc hiv doc survey favor pt
growth hiv new start modest past sever year prep adopt
non-infect patient robust exit exit
big driver truvada could see anoth leg growth phase
prep studi descovi success
diversifi virolog franchis
view gilead acquisit kite strateg ad
cell-bas therapi platform vs ad singl product yescarta inde dont expect
inflect point yescarta consensu expect
early/mid stage progress grow indic base line dlbcl mcl cll
myeloma etc near-term filgotinib data ra import view
given weve alreadi seen success phase ra consensu doesnt eclips
addit nash import space gilead admittedli
underwhelm data nash asset compani bullish ahead
selonsertib data make easl meet vienna april
impact one
valuat thought
price target base sum-of-the-part approach estim npv
valu key franchis use wacc differ growth rate
major product assumpt valu hiv hcv
car-t product pipelin net
cash
expect
sinc sept ipo share gain compar declin
nbi index period look progress
gritston clinic program advanc tumor-specif neoantigen tsna platform
proof concept data trial enrol progress ind give investor
comfort around long term prospect platform compani expect
provid proof concept data program potenti data
esmo congress sept oct barcelona major de-risk event
platform view addit updat research program
recent updat bispecif program see thought bispecif program
progress provid opportun year show
compani continu head right direct though time updat less
valuat thought
price target base npv analysi forecast risk-adjust sale
probabl success granit colorect cancer bladder cancer gastric
cancer non-smal cell lung cancer nsclc assum potenti launch
addit
commerci slate treatment pancreat cancer nsclc
initi market entri begin earli
probabl
use discount rate program line biotechnolog peer
size develop stage given assumpt deriv valuat
granit slate net cash result
npv support price target overweight rate
expect
stock trade ex-pipelin clinic catalyst capabl drive re-rat
challeng year vs nbi index neg
sentiment continu linger follow epacadostat setback along
fda approv restrict expect label olumi outlook certainli
obscur otherwis solid commerci perform core franchis jakafi
howev given robust uptak mf pv continu forecast strong
growth capabl anchor near term y/i growth us sale
line consensuspart compound-annual-growth-rate con
primari driver share like pipelin howev view
share trade littl valu attribut develop portfolio see
corp life ido trade ex-pipelin intrigu mix
oncolog assetsinclud new product expand indicationsw look
seri posit regulatori commerci updat next month
potenti drive re-rat event includ potenti approv jakafi
steroid-refractori acut gvhd possibl registr enabl data
olumi atop dermat lilli lead develop jakafi gvhd
itacitinib gvhd addit updat
citadel program monotherapi r/r fl mzl mcl
believ would better serv concentr develop effort
later stage pipelin focus near-term top-lin growth out-licens earlier
stage pipelin continu see compel share upsid current levelswith
set potenti begin turn sentiment
valuat thought
price target base sum-of-the-part npv analysi forecast sale
patent expiri key product jakafi baricitinib assum zero termin valu
use discount rate probabl adjust appropri
base deriv valu jakafi baricitinib
royalti broader pipelin net cash
expect
compani split remain overhang share head
ironwood finish vs nbi index enter
midst transit two separ compani ironwood includ linzess
gi product co includ asset sgc mechan orphan diseas
contribut uncertainti separ complet earli
linzess sale still healthi y/i growth start moder
competit threat bausch see coupl reduct net price
could weigh sale trajectori next month see room upsid
go remain sidelin await sign linzess volum increas
phase pipelin progress gi portfolio
linzess franchis potenti pitfal
linzess franchis allergan sale abil move needl forward
volum growth manag estim million patient current
treat million market enter expect continu effort
linzess sale team drive penetr sever headwind potenti
serv limit sale upsid among net-pric declin due increas
payer pressur manag stress access maintain
compani need reli volum gain continu growth furthermor competitor
trulanc sale synergi pharma acquir bausch see bhc/irwd
bausch acquir synergi pharma asset bring anoth
competitor mix vie patient addit recent approv motegr
shire provid ad competitor could imped volum growth
pipelin help reacceler growth
anticip china food drug administr complet review
linzess earli potenti drive addit growth ou follow cfda
news posit top-lin data phase linzess abdomin symptom trial
announc sometim ironwood find potenti develop partner
gerd asset current phase see opportun addit
acceler growth sentiment chang ironwood
valuat thought
target price per share base sum-of-th part npv analysi valu
irwd linzess program net cash
expect
cover medic devic analyst kristen stewart share fare wors drg
index vs under-perform weight toward litig
concern talcum powder view weak topic overdon could
remain overhang least fundament think could
challeng year particularli pharma given multipl gener launch biggest
zytiga gener launch inde consensu pharma growth
could trough vs view medic
devic consum segment enough off-set neither
acceler phase posit impact growth henc suspect share
unlik see multipl expans valuat isnt high current level
isnt attract enough chang ew thesi view growth profil
pharma look compel rel
pharma headwind play
consensu forecast reflect sever pharma headwind includ zytiga
us remicad velcad concerta tracleer
push ww pharma growth overal market growth
like commerci profil tremfya erleada imbruvica darzalex continu
make meaning contribut oncolog segment dont see impact
enough off-set headwind inde market share benefit recent
eclips data tremfya psoriasi could weight toward similar
time-frame like share gain darzalex base recent maia data myeloma
immunolog oncolog biggest contributor pharma
revenu could experi volatil wed view segment
unlik meaning ahead expect pipelin perspect esketamin
depress erdafitinib urotheli cancer new launch
expect make good progress anti-bcma car-t front
myeloma well zejula prostat cancer recent meet highlight
signific competit myeloma multipl player evalu bcma target
resourc mindshar base darzalex step develop pace
medic devic consum mostli stabl
devic busi see gener stabl trend though optic growth
improv declin diabet busi sold isnt headwind growth
view depuy synth orthoped franchis growth like modest
expect continu advanc orthotaxi system goal launch
expect steadi trend js surgic franchis higher growth advanc surgic
busi also expect verb surgic partnership continu advanc
robot surgeri platform work market launch growth
continu vision solid trend contact len surgic unit
intervent solut busi continu grow double-digit basi
underli basi driven strong growth biosens webster electrophysiolog
franchis well increas contribut cerenovu stroke intervent
may greater investor interest devic well consum bolt-
deal manag broadli discuss
valuat thought
given pharma headwind talc concern view multipl peer
estim unlik expand unknown far ahead investor price
re-acceler pharma growth
expect
share took longer expect undergo signific re-rat base
mostli phase win keytruda finish year strong perform
drg index head think sentiment around stock posit
view continu keytruda domin across i/o becom
pronounc cours year investor look see domin
keytruda realli lung across i/o gener rcc melanoma
recogn wont see initi bolu patient mani recent label
expans increas emphasi magnitud keytruda upsid quarter
inde saw weak share earn beat expect
note keytruda mostli exceed street expect
yet dramat beat consensu despit robust results/lin extens
larg nsclc market view play given greater
contribut ou sale top consist market share gain nsclc us
result maintain bullish outlook merck
keytruda domin i/o could mean much share upsid
merck stori continu root aggress growth keytruda franchis
look forward beyond suspect compani see consist
robust keytruda upsid lung stori begin play eventu renal
consensu us keytruda sale impli growth ww basi
see clearli doabl given recent trajectori ultim forecast keytruda could
repres total revenu help mitig diabet loe
beyond lung think progress across multipl indic help acceler
keytruda growth beyond sever phase dataset expect across
tnbc emphasi upcom dmc review data origin
anticip phase neoadjuvant/adjuv tnbc detail
result rcc addit near-term approv propel
keytruda growth adj melanoma februari well recent approv kn-
lung
pipelin diversif need larg keytruda focus
evid need broaden product mix divers away oncolog
view share perform primarili driven keytruda franchis
cours outsid keytruda think investor close watch gardasil/gardasil
extension/transit regimen along lynparza metastat breast
cancer follow recent posit string result consensu
given
valuat thought
pt reflect blend averag price-to-earnings multipl analysi assum
merck share hold forward year price-to-earnings multipl ep impli
valu approxim dcf analysi assum wacc
termin growth suggest intrins valu approxim
expect
major relugolix catalyst core focu
rel limit news flow perspect myovant share end
year well nbi index vs nbi index largelyw suspectdu
de-risk compani key asset relugolix driven continu posit clinic
regulatori data competitor neurocrin elagolix see abbv/nbix thought
orilissa elagolix approv look myovant build
tailwind on-going phase relugolix clinic program anticip read
across three major indic uterin fibroid phase liberti data
expect data expect endometriosi spirit data like
prostat cancer hero trial fulli enrol data expect
could push share increment higher see myov takeaway myovant
orilissa perform provid insight market opportun
continu posit long-term myovant pipelin compani given
potenti upsid
underserv women health market inde see
opportun multipl player market includ neurocrin orilissa
myovant strategi includ add-back hormon therapi relugolix tablet vs
separ orilissa still need play look sale orilissa endometriosi
determin potenti uptak curv relugolix stress effort
develop market remain underway forecast minim sale
expand vs consensu respect
substanti improv initi commerci success provid upsid myov
valuat thought
valu myovant base npv analysi deriv valuat
compris relugolix probability-of-success
net cash
expect
challeng year neurocrin saw share end year
vs nbi index believ investor re-assess share high-
growth high-qual smid cap biotech follow phase setback pediatr
tourett syndrom ingrezza t-forc gold see thought tourett
gold miss view ts opportun remov valu driver long
term ingrezza remain high-growth asset tardiv dyskinesia forecast sale
compound-annual-growth-rate peak potenti vs consensu henc ts
setback drastic chang thesi provid attract entri
share go view see neurocrin bioscienc move beyond ts
ingrezza still upsid potenti
note ingrezza goe tailwind multipl sourc includ
double-digit sequenti script growth stabil revenue/script
vs prior increas prescrib experi expand
sale forc larger expect ingrezza continu make stride close
two year sinc approv look januari confer wouldnt
surpris see neurocrin provid ingrezza sale consist
meet sure guidanc offer call
orilissa sale pipelin catalyst capabl provid addit share gain
abbvi orilissa potenti billion dollar drug reflect
lucr deal neurocrin royalti sale project royalti
peak see abbv/nbix thought orilissa elagolix approv
expect complet orilissa nda submiss uterin fibroid uf
see indic larg de-risk given prior approv endometriosi
strong phase data uf addit pipelin asset includ phase data
expect well ongenti investig treatment
parkinson diseas whose nda file expect occur
valuat thought
valu neurocrin base npv analysi forecast sale orilissa
orilissa assum tier royalti rate zero termin valu
discount rate ingrezza model us sale td base assumpt
deriv valuat compris orilissa royalti
ingrezza rest pipelin mileston net cash
expect
share among best perform pharma vs drg index
larg driven increas consensu expect multipl expansionup
turn sinc begin year given increasingli posit ep outlook
ultim agre fundament much solid foot vs previou year
wed argu broadli reflect multipl current level wed expect
upsid increment expect convers larg
remain center revenu growth pipelin expansion/execut howev unlik
recent year anticip focu begin move away transform deals/larg
restructur year unfold increas headwind face franchis
perceiv late-stag pipelin asset potenti high-impact
troubl see suffici sustain growth beyond given current
late-stag pipelin forecast revenu compound-annual-growth-rate support
equal weight rate pt
restructuring/ceo transit unlik chang strategi
follow recent convers manag dont believ incom ceo albert
bourla market large-scal transform deal inde note
outgo ceo ian read need larger deal manag declin revenu base
recent year revenu base ian read took ceo role
vs estim note much convers past
year focus deal consensu revenu growth expect rang
averag seem us overal
strategi go forward instead one fine-tun mr bourla seat
smaller-scal deal product-specif d-centric necessarili
yield cost save signific oper synergi
innov remain growth driver headwind unchang essenti
innov perform well continu growth across portfolio
key product ibranc eliqui trend expect continu fact
lyrica loe could meaning product pressur though alreadi larg
price share consensu ww y/i product-specif
basi look ou ibranc growth outpac us given challeng face
use adjuv set could major driver data expect time
xtandi earlier use substanti growth driver launch gener
zytiga launch novemb jnj erleada could growth concern consensu
growth look reason y/i i/o dont get
impress hungri becom leader space appear still
emphasi develop novel i/o i/o combin therapi term late-
stage asset garner signific enthusiasm point advanc
tafamidi tanezumab expect high interest investor includ
tafamidi file us eu follow global launch addit ph
tanezumab data includ long-term safeti re-risk/dict use pain
valuat thought
current view enterpris base valuat methodolog appropri
sum part analysi price target reflect blend averag
price-to-earnings base compar analysi assum multipl expans appli
current year multipl forward year earn dcf assum wacc
termin growth
expect
follow al amyloidosi setback littl anticip way news flow
help drive re-rat
mark clear setback vs nbi index
unexpect discontinu al amyloidosi
primari driver share modeland suspect rest streetlarg
drive neg sentiment persist follow announc last april
littl expect way clinic updat meaning news flow
expect sentiment persist given overal lack near-term value-cr event
rather expect provid increment updat among news flow
like enrol updat phase pasadena studi anti-alpha-synuclein
antibodi prasinezumab parkinson diseas remain
major driver share valuat model partner roch lead develop
studi track top-lin data
updat earlier stage asset anticip includ limit pharmacodynam
data attr amyloidosisalthough program remain well behind
pfizer tafamidi number silenc approach preclin programsan anti-
tau partner celgen anti-amyloid betamay move forward given
like limit valu ascrib three drug expect littl share impact news
given cash posit see suffici fund avail support
develop like least off-set concern potenti need addit
capit absent opportun meaning de-risk data next year see littl
potenti signific share movement
valuat thought
price target per share base sum-of-the-part npv analysi valu
share collabor roch pipelin asset
combin project net cash posit support
pt
expect
competit risk eylea remain critic overhang
share perform margin better nbi index vs larg
back continu albeit deceler eylea growth look remain
cautiou eylea trajectori sale growth consensu
view sentiment like test novarti brolucizumab formal
approv late begin take share market alreadi reach
matur view competit risk eylea underappreci street
compound-annual-growth-rate vs consensu look name
space concentr risk celgen alexion etc
multipl contract frequent occur prior initi market share loss see regeneron
dupix launch strong expect high
success point dupix launch clear howev appreci
uptak atop dermat ad see posit initi sign nasal polyp see
thought dupix nasal polyp data asthma see
brandimpact suggest solid dupi asthma start think caution
warrant given alreadi high expect view growth seem aggress
cautiou also look compound-annual-growth-rate
vs consensu particular consensu outer year forecast dont seem
broadli factor competit ad space clearli compani develop jak
inhibitor acut focus ad includ lilli could first set phase
data olumi
pipelin pick slack eylea
recent approv libtayo centerpiec regeneron oncolog strategi
antibodi formal approv cscc antibodi
approv nich indic longer path expand label broadli
includ nsclc inde suspect merck keytruda bristol opdivo off-
label penetr cscc clearli leader nsclc space remain
cautiou regeneron io strategi overal given big lead across biopharma
develop mani io/io combo etc cscc specif model
sale vs consensu
valuat thought
maintain pt go valu eylea
ab partnership sanofi praluent dupix kevzara
compani earlier stage pipelin net cash impli total valu
look forward forecast us eylea sale vs consensu
total revenu vs consensu bottom-lin see non-gaap ep vs
expect
although share end year broader market nbi index vs
nbi index skeptic upsid adcetri hodgkin
lymphoma continu persist indic share fall
dramat compani miss revenu expect adcetri repeat
channel check confirm grow support adcetri regimen abvd see
seattl genet hl survey confirm posit outlook head
remain encourag adcetri potenti hl compani move past earli
adopt increas effort sale forc see ramp sale
especi like label expans includ favor north american
cohort data prior approv forecast adcetri sale
y/i vs consensu see north american
see addit upsid like adopt follow impress
resultssupport one faster sbla approv see thought
adcetri approv continu see longer term opportun
adcetri seattl whole addit patient label roughli
size popul clear unmet need space given
patient benefit littl standard-of-car chop therapi look increas
stabil compani expand pipelin see support
late stage pipelin come shape
beyond adcetri commerci execut includ number catalyst seattl
intrigu pipelin suspect street give much valu data
pivot enfortumab vedotin ev urotheli cancer studi expect
could potenti support bla submiss view meaning
event seattl transit compani pure hematolog focu broader
divers hematology/oncolog focu enrol pivot tucatinib
breast cancer studi complet could set data
earli monotherapi tisotumab vedotin innovatv platinum-resist
ovarian cancer phase expect start earli overal continu
encourag seattl effort expand portfolio continu evolut
matur commerci stage compani multipl valu driver beyond adcetri
valuat thought
price target base npv-base sotp analysi seattl key asset
use estim wacc termin growth rate valu adcetri
approxim tucatinib
pipeline/platform year-end cash result
total valu approxim
expect
outlook like significantli impact gener
share pressur vs nbi index given increas
competit dynam compani core pah franchisewhich like continu
product adcirca remodulin togeth account
revenu face gener competit gener adcirca launch august
lead rapid sale declin q/q look continu signific
pressur revenu go vs consensu time gener
remodulin remain uncertain continu critic overhang stock
compani anticip launch competit respons much delay remodulin
pump manag tout potenti slow price eros although
recogn substanti improv eas administr channel check
suggest like minim market impact nonetheless launch subsequ uptak
remain key catalyst stock unexpectedli robust posit respons
capabl drive upsid
rest portfolio unlik off-set pressur
although posit freedom-ev studi admit win compani
continu see littl upsid orenitram sale see thought freedom-
ev result channel check reveal mani prescrib alreadi use
off-label combin background inhibitor era kol continu
favor jnj uptravi forecast littl impact expect label expans
current forecast modest growth vs consensu sale
trajectori like remain key focu investor forecast declin tyvaso
sale vs consensu littl impact recent in-licens agreement
ralinepag arena continu believ could tough year unit
contribut outlook contract barclay total revenu y/i
vs consensu barclay gaap ep vs consensu
near-term pipelin catalyst focus life cycl manag impact like
expect top-lin result phase combin trial tyvaso group
pah un-blind schedul around although potenti file could occur
august ip posit remain unclearsuggest like limit impact
stock resubmiss trevyent nda also plan
steadym acquisit remov overhang tyvaso re-fil similarli unlik
impact share much dont assign valu asset dinutuximab phase
sclc phase ipf platform transplant franchis given risk
level develop time wont help mitig eros curv see
 takeaway scienc day
valuat thought
price target share base sum-of-th part npv analysi
forecast sale remodulin tyvaso adcirca account impact
prior patent expir forecast sale orenitram patent expir
assum termin valu product use discount rate believ
appropri reflect risk asset revenu stream go forward assign
remodulin tyvaso adcirca orenitram
unituxin combin net cash posit support
expect
one de-risk stori larg cap biotech vertex significantli outperform
nbi index vs even current level still see opportun
continu momentum approv strong earli launch
symdeko robust phase tripl combo data see thought tripl
phase data underwhelm clinic data competitor cystic
fibrosi cf space vertex appear set domin cf landscap forese
futur beyond cf pipelin asset overshadow point rest
busi includ pain see third posit poc highlight
potenti pain sickl cell/beta thal see thought
clinic progress antitrypsin fsg emerg
could present meaning opportun diversif said dont view non-
cf pipelin differenti de-risk enough add signific valu
remain bullish cf portfolio overal
execut cystic fibrosi critic
phase data second tripl combo expect
vertex select regimen move forward market expect tripl combo
ultim come market time submiss approv opportun upsid
het-min patient current untreat anticip price premium
recent launch symdeko model net rapid launch would add meaning
upsid expect vertex guid submit nda later
see thought tripl combo updat establish
safeti profil tez/iva backbon larg unmet need among het-min patient
clinic benefit shown phase rapid approv like forecast launch
model tripl combo revenu vs consensu see vertex
pharmaceut attract profil tripl data
pipelin could upsid need de-risk
focu vertex cf rightli howev could year
non-cf pipelin start garner attent phase data acut pain
expect mid could lead pivot studi indic posit
poc data three type pain acut chronic neuropath think target
channel may right approach mani failur throughout industri target
partnership crispr beta-thalassemia sickl cell fit well
orphan diseas well understood biolog model vertex prefer
encourag program advanc clinic hold howev data sever
year competitor program advanc see wait see program
valuat thought
pt base sum-of-the-part npv analysi forecast sale
patent expir addit year potenti hatch-waxman extens
assum termin valu orkambi kalydeco symdeko tripl combo risk adjust
use discount rate forecast period appropri reflect
risk portfolio given assumpt assign valu
kalydeco orkambi symdeko tripl
combo combin pipelin valu net cash result
total npv
expect
onpattro approv hereditari amyloidosi hattr polyneuropathi
transit commerci compani investor focu would larg
onpattro launch although expect rather low anticip cover geoff
meacham tafamidi approv launch major valu driver would
strong onpattro launch base number start form patient expand
access program expect beat expect consensu estim
provid upsid stock sever data catalyst includ
inclisiran hypercholesterolemia givosiran acut hepat porphyria lumasiran
primari hyperoxaluria could provid increment upsid stock addit upsid
could vutrisiran optim develop path wild-typ attr market
onpattro vutrisiran
believ key success onpattro launch would alni abil penetr
attr patient mix cardiomyopathi polyneuropathi patient identif
physician educ would import gain initi market share although
disadvantag see iv administr temporari issu gen vutrisiran could
replac onpattro rapid path plan vutrisiran wild type
attr patient would disclos see optim path includ activ
compar shorter time surviv endpoint readout potenti surrog endpoint
interim analysi acceler approv
givosiran lumasiran program
top-line result givosiran envis studi acut hepat porphyria expect
earli could potenti support approv late us
eu inclisiran partner mdco initi studi hypercholesterolemia data
readout would expect lumasiran illuminate-a primari
hyperoxaluria type start top-line result expect late
valuat thought
fitusiran givosiran
price target base sum-of-the-part probability-adjust
assign technolog platform acknowledg exact
valuat technolog subject believ addit valu technolog
platform justifi given capabl potenti transferr clinic develop
clinic asset includ valuat assign termin
valu clinic asset use discount rate reflect commerci risk
believ appropri given probability-adjust revenu
expect
follow larg flat year expect sever catalyst move stock
although chanc low see upsid potenti top line robust palynziq
launch compani would guid y/i growth investor
focu howev would includ data updat hemoa achondroplasia
expect larg posit data valrox hemoa trial
like first hemoa gene therapi market updat program
would import assess durabl price payer discuss
achondroplasia expect larg posit data base data see upsid
updat hemoa achondroplasia
head start hemophilia gene therapi expect report valrox studi
vg/kg dose fviii level may serv support acceler
approv reduct annual bleed rate week would requir full
approv expect like posit outcom valrox would first hemoa gene
therapi market howev data trial would import
assess durabl importantli price discuss payer vosoritid
trial achondroplasia fulli enrol top line data anticip
expect posit data primari endpoint annual growth veloc week
baselin base data expect posit move stock
top line growth palynziq revenu expect
consensu estim fall upper end
guidanc consensu estim repres
growth y/i consensu estim palynziq rather modest see
upsid potenti expect posit stock move compani guid top line
valuat thought
price target base sum-of-the-part probabl adjust discount cash dcf
valuat key program
pegvalias naglazym assign termin valu
clinic asset use discount rate reflect commerci risk believ
expect
investor main focu would still bcma competit landscap impact
blue follow updat eha see mani emerg new
therapi target bcma multipl myeloma increasingli competit continu
view blue best importantli like first market current
stock reflect valuat bcma see signific upsid celg
cover geoff meacham remain commit move earlier line
therapi lentiglobin investor view larg derisk beta thalassemia bt
sickl cell diseas scd expect approv bt see upsid though
price lentiglobin would significantli higher consensu
follow updat eha multipl competitor data
view advanc asset high bar efficaci safeti orr
cr pt prior line therapi singl digit
neurotox competitor show initi impress orr cr good safeti
profil data immatur larg line subpar compar earli
data believ product superior better safeti profil would eventu
stand long run expect key player bcma target therapi
mm given diminish return high cog
lentiglobin beta-thalassemia sickl cell diseas bt/scd
multipl data updat continu support lentiglobin like viabl product
bt scd expect approv bt like posit outcom scd
potenti acceler approv expect larg price see upsid
price lentiglobin would significantli higher consensu assumpt
valuat thought
price target base sum-of-the-part probability-adjust discount cash
includ lentiglobin lenti-d
assign termin valu clinic asset use discount rate
reflect commerci risk believ appropri given probability-adjust
expect
disappoint updat investor low expect rubraca revenu
investor near-term focu remain rubraca sale believ parpi
drug class could expand earlier line ovarian cancer indic includ
prostat breast bladder cancer independ compani
approv parpi would pose signific interest compani would like access
drug class see signific upsid long-term potenti expect
updat regulatori submiss prostat cancer drive stock
see addit upsid potenti posit updat atla data bladder
cancer
rubraca clinic catalyst provid upsid
expect longer follow provid support rubraca
prostat cancer support potenti acceler approv path addit
expect see posit data updat atla studi bladder cancer
rubraca launch expect
expect larg flat modest growth us launch ema approv rubraca
line mainten set ovarian cancer could provid addit revenu
growth note consensu estim
us
valuat thought
price target base sum-of-the-part probability-adjust discount
cash flow dcf includ rubraca assign termin valu
clinic asset use discount rate reflect commerci risk believ
expect
see multipl upsid potenti given current stock reflect
cash valu royalti partner nv cover emmanuel
papadaki see upsid nv receiv approv spinal muscular
atrophi sma may announc higher price vs investor consensu
well robust launch success ip extens us wholli own
wetamd gene therapi program investor far still give limit valu
program see high probabl proof concept base encourag data
first cohort see signific upsid protein level could achiev
lucenti level continu improv inject spare addit see
free option potenti royalti dmd model
compani report data first cohort pt clear dose-
depend respons observ biomark anti-vegf protein level clinic
efficaci lucenti spare cohort complet enrol pt earli
expect see mon data includ mon mon biopsi data
mon clinic data well longer follow first cohort see high bar
gene therapi product wetamd expect see lucenti spare
zolgensma support current valuat addit upsid
license nvs/avx made substanti progress program zolgensma
use vector spinal muscular atrophi sma fda approv expect
may elig royalti mid-singl low-doubl digit percentag
see upsid higher price vs consensu zolgensma robust initi
launch yr ip extens us beyond current
valuat thought
price target base probability-adjust discount cash flow
assign technolog platform acknowledg assign
exact valuat technolog subject believ novel aav vector platform
promis develop potenti cur gene therapi assign termin valu
clinic asset use discount rate reflect commerci risk believ
appropri given probability-adjust revenu
expect
impress dmd gene therapi data progress multipl clinic program
transform commerci compani back pipelin stori
expect larg inline/modest upsid revenu guidanc exondi vs consensu
us sale investor focu would dmd gene therapi updat clinic
progress cover cover geoff meacham report
dmd gene therapi data cautiou sentiment due competitor
data believ set high bar efficaci safeti potenti meaning
first market advantag see addit upsid promis safeti profil
ppmo updat posit biomark data protein level optim dose
limb-girdl muscular dystrophi golodirsen approv although
view high risk
expect larg in-line revenu consensu revenu fall
middl guidanc expect line/modest upsid guidanc
vs consensu see addit revenu upsid golodirsen would
approv
alreadi start trial dmd gene therapi dec expect see
fda feedback detail trial design begin jan competitor
would report initi biomark data begin jan investor
seem high expect given acceler time line prior anticip
similar level protein compar srpt program averag addit
competitor would also report initi dmd gene therapi data cohort like
month data first patient alway view like compar
clinic profil optim dose believ set high bar like would
first market meaning advantag competit larg market believ
could pose potenti meaning competit slbd would need address ip issu
like infring ip possibl safeti issu
valuat thought
price target base sum-of-the-part probability-adjust discount cash
microdystrophin gene therapi assign
technolog platform acknowledg exact valuat
technolog subject believ addit valu technolog platform
includ gene therapi dmd/lgmd ppmo dmd justifi given valu
could potenti gener assign termin valu clinic asset use
discount rate reflect commerci risk believ appropri given probability-
expect
mix updat hemophilia data aug investor gave limit hemoa
opportun sever move part import upsid
would still hemoa updat believ prophylact treatment steroid
address cytotox t-cell immun respons seen pt longer follow
address durabl question rais competitor data investor expect luxturna
launch gener low sell-sid consensu revenu see upsid
better launch execut well progress pomp gene therapi program
saw longer follow data first cohort larg durabl
fviii level expect see data pt cohort
vg/kg steroid prophylact treatment longer follow prior pt
would look well control cytotox t-cell respons durabl fviii level
throughout trial debat optim fviii level vs
believ fviii level would suffici base kol feedback
durabl would import differenti factor payer physician
luxturna launch expect
expect see larg in-line top-line consensu reach revenu
consensu estim us sale expect provid
guidanc year see addit upsid partner nv
cover emmanuel papadaki good ex-u launch luxturna royalti
valuat thought
price target base sum-of-the-part probability-adjust discount cash
assign termin valu clinic asset use
discount rate reflect commerci risk believ appropri given
probability-adjust revenu risk includ regulatori approv revenu potenti
expect
convert meaning commerci compani approv
crysvita x-link hypophosphatemia initi launch show good uptak pediatr
patient importantli difficult-to-penetr adult pt expect beat
consensu crysvita revenu see addit upsid top-line
approv lc-faod investor give limit valu rare
gene therapi program low expect initi data
would look good safeti data sign initi activ
around over-the-counter defici expect addit dose escal
over-the-counter defici investor low expect given inconclus data
first cohort similarli investor low expect first cohort data
program howev given good safeti far expect see improv
efficaci dose escal see risk/reward favor head updat
lc-faod over-the-counter defici program
expect see larg in-line top-line crysvita consensu reach
crysvita revenu consensu estim crysvita
expect beat given initi good launch us eu see
addit upsid approv lc-faod
valuat thought
price target base sum-of-the-part probability-adjust discount
cash flow dcf includ burosumab rhgu trihep faod
assign technolog platform acknowledg exact
valuat technolog subject believ addit valu aav gene
therapi platform justifi given recent progress assign termin valu
clinic asset use discount rate reflect commerci risk believ
expect
follow solid first take solid expect cash still sore spot
exemplifi initi long-standing construct stanc name respect
bar free cash-flow mystic trial domin invest case
reach conclus key io asset imfinzi fail meet os stage iv nsclc
mystic denouement dark night farxiga met primari endpoint
declar declar aha call feedback said product stori remain
key overal compani continu tick key box good beat today
key asset clearli infect trajectori within oncolog view continu
frame good risk-reward addit upcom datapoint io doublet kestrel
lynparza polo pancreat preview depth see research
link restructur capital-expenditure declin expect visibl product inflect
duli reflect cash-flow anticip growth china em
even price-to-earnings core ep compound-annual-growth-rate dec azn
look inexpens sinc march azn remain top pick
valuation/catalyst dec price-to-earnings dividend yield
ep compound-annual-growth-rate vs sector compound-annual-growth-rate dividend yield catalyst imfinzi
expect
volatil year genmab failur darzalex solid tumour
may deliv big hit investor sentiment persist throughout broader
sell-off growth name weve seen back half year said
remain posit underli growth stori darzalex expect maia
data includ label file expect could see inflect
script particularli follow posit recept data recent held
american societi hematolog confer see genmab a/ bring charg back
san diego eu pharmaceut eu pharma wrap cart
bispecif fore
expect
upgrad novarti ew juli tanker turn right thing tight
spot acknowledg clear sentiment momentum follow spate good
news serendipit gilenya ipr win well engin avx
invest alcon spin buy-back howev mid-term growth challeng pharma
view consensu growth expect
uncomfort predict typically-less-resili dosag ip hold gilenya gilenya
safeti updat head-fak continu see structur
challeng flagship oncolog franchis legaci small molecul asset face
kymriah importantli remain consensu key growth asset
entresto/cosentyx whilst former inflect defi expect
pharmaceut law relaunch latter look set face earli elev
competit pressur follow geoff meacham post best-in-class data
risankizumab file april js geoff meacham head head eclips studi
demonstr signific improv adult moderate-to-sever plaqu psoriasi
eclips take displac confirm tremfya among oral jak
abbvi upadacitinib trial select underway fda ema applic
submit posit psoriat arthriti data equat ankylos spondyl
data tortuga filgotinib gilp/gild serv remind competit
environ key cosentyx asset would find outsid plaqu psoriasi
set crystallis long-standing point caution us earn
price pressur ground pipelin caution
inflamm downgrad uw eclips back uw
valuation/catalyst dec price-to-earnings dividend yield
ep compound-annual-growth-rate vs sector compound-annual-growth-rate dividend yield catalyst avxs-
fda/ema approv sma type entresto paragon
expect
critic year ucb pipelin perspect underweight rate
deriv us pessimist outlook forthcom data readouts/catalyst
rel street wed note fda advisori committe meet
romosozumab januari revenu current financi model
follow addit phase data rozimab itp present along
compani result first phase data target psoriasi
asset bimekuzimab see ucb sa barclay call feedback ucb sa
ring new year even adcom ucb sa eclips
readthrough pathway throw shade
gena wang phd cfa geoff meacham ph emmanuel papadaki phd cfa herebi certifi view express
research report accur reflect person view subject secur issuer refer research report
part compens directli indirectli relat specif recommend view express research
